Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XBIT
XBIOTECH INC.
NASDAQ
$2.27
▼ DOWN 1.30% (-0.03)

KEY STATISTICS

Market Cap$69.21 M
52w High$3.44
52w Low$2.09
Dividend Yield14.91%
FrequencySpecial
P/E-1.53
Volume6.96K
Shares Out.30.49M

COMPANY

LEADERSHIP

Sushma Shivaswamy
CHIEF EXECUTIVE
Sushma Shivaswamy

COMPENSATION 2026

Salary$1,205,083
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$10,498
Total$6,245,581

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 15, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
87

PRICE

$2.27 ▼ DOWN 1.30% (−$0.03)
$2.27$2.28$2.30$2.319:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.27

About XBiotech Inc.

https://www.xbiotech.com ↗

XBiotech Inc. is a Texas-based biopharmaceutical company developing True Human monoclonal antibodies and interleukin-1 alpha therapies for inflammatory, infectious diseases, and COVID-19.

INDUSTRY

Biotechnology

A PRODUCT XBIOTECH INC. IS KNOWN FOR

Natrunix™
Natrunix™

Natrunix™ is a monoclonal antibody targeting IL-1α, showing promise in clinical trials for pancreatic cancer and rheumatoid arthritis, with potential as a breakthrough anti-inflammatory therapy.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
REGN COMPARE
XFOR COMPARE
XNCR COMPARE

Revenue by Products

IconPRODUCTQ1-2022Q2-2022Q3-2022Q4-2022
Manufacturing Revenue$500K $1.53M ▲$1.68M ▲$300K ▼
Clinical Trial Service Revenue$0 $0 $0 —

ETFS HOLDING THIS STOCK

ETFS HOLDING
7
LISTED HERE
6
RANKED BY POSITION SIZE
VXF
0.00% · 200.2K
IWC
0.01% · 79.6K
BSVO
0.01% · 59.5K
AVSC
0.00% · 13.2K
SILX
0.30% · 9.7K
GERM
0.48% · 6.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
16.51%
HOLDERS
65
TOP 12 OF 65 · RANKED BY POSITION SIZE
Blackrock Inc.
1.1M sh · $5.83M
Blackrock Fund Advisors
1.0M sh · $10.26M
Vanguard Group Inc
819.2K sh · $2.18M
Millennium Management LLC
416.3K sh · $1.11M
Blackrock, Inc.
302.4K sh · $804.35K
Credit Suisse AG/
248.3K sh · $2.02M
Geode Capital Management, LLC
231.0K sh · $543.17K
Blackrock Institutional Trust Company, N.A.
216.1K sh · $2.19M
Rbf Capital, LLC
200.0K sh · $532K
Ameriprise Financial Inc
186.8K sh · $446.44K
Morgan Stanley
165.6K sh · $389.05K
Bridgeway Capital Management, LLC
98.4K sh · $231.35K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

★
DIRECTOR
Rademaker Craig Evan
Purchase · 92.1K shares
2025-10-01
★
DIRECTOR
Soffer David Spencer
Purchase · 51.0K shares
2025-10-01
★
DIRECTOR
Kuendig Thomas Martin
Purchase · 79.1K shares
2025-10-01
★
DIRECTOR
Troy Tevi David
Purchase · 56.0K shares
2025-10-01

SECTORS PEERS

PEERPRICE
RLMD$4.33COMPARE
ADAG$3.68COMPARE
FBIO$2.77COMPARE
ACRV$2.06COMPARE
ACET$9.06COMPARE
GANX$1.77COMPARE
NTRB$4.46COMPARE
TCRX$0.75COMPARE